Amylin receptor agonist: difference between revisions
Diff·revision 12 → 13·14:39, 12 Mar 2025
Difference between revision 12 and revision 13 of Amylin receptor agonist. 2 lines changed; the page grew by 287 bytes.
| Revision 12 — 03:33, 19 Feb 2025 CommaCarys (talk) the storage condition applies to the unopened pen; say so 3,622 bytes +90 | Revision 13 — 14:39, 12 Mar 2025 PrepHPLC_Pia (talk) alphabetise the see-also list 3,909 bytes +287 | ||
|---|---|---|---|
| 25 | Cagrilintide monotherapy produced approximately 10% weight reduction at 26 weeks in a phase 2 trial. In combination with semaglutide, reported weight reduction exceeds that of either component alone; the combination programme is covered at [[CagriSema]].{{r|lau2021}} | 25 | Cagrilintide monotherapy produced approximately 10% weight reduction at 26 weeks in a phase 2 trial. In combination with semaglutide, reported weight reduction exceeds that of either component alone; the combination programme is covered at [[CagriSema]].{{r|lau2021}} |
| 26 | 26 | ||
| + | 27 | The gastrointestinal adverse-effect profile resembles that of the incretin agonists, with nausea predominating and concentrated during escalation. Whether combining two agents that both delay gastric emptying compounds this is a question the combination trials address only indirectly. | |
| + | 28 | ||
| 27 | == References == | 29 | == References == |
| 28 | {{reflist}} | 30 | {{reflist}} |